Lenvatinib

Generic Name
Lenvatinib
Brand Names
Lenvima 10, Kisplyx, Lenvima
Drug Type
Small Molecule
Chemical Formula
C21H19ClN4O4
CAS Number
417716-92-8
Unique Ingredient Identifier
EE083865G2
Background

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.

Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

Indication

Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions
Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
Associated Therapies
-
Clinical Trials
Related News

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

First Posted Date
2021-08-12
Last Posted Date
2024-11-05
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
39
Registration Number
NCT05003700
Locations
🇨🇳

Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

First Posted Date
2021-08-12
Last Posted Date
2023-04-25
Lead Sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Target Recruit Count
16
Registration Number
NCT05001724
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

First Posted Date
2021-08-04
Last Posted Date
2021-12-08
Lead Sponsor
Dr Joanne CHIU
Target Recruit Count
46
Registration Number
NCT04989322
Locations
🇭🇰

Queen Mary Hospital, Hong Kong, Hong Kong

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

First Posted Date
2021-07-27
Last Posted Date
2024-02-22
Lead Sponsor
GI Innovation, Inc.
Target Recruit Count
430
Registration Number
NCT04977453
Locations
🇺🇸

Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York, United States

🇺🇸

Carolina Biooncology Institute, Huntersville, North Carolina, United States

🇰🇷

The Catholic University of Korea St. Vincent's Hospital, Suwon-si, Kyeonggi-do, Korea, Republic of

and more 4 locations

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

First Posted Date
2021-07-26
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
730
Registration Number
NCT04976634
Locations
🇺🇸

University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047), Tucson, Arizona, United States

🇺🇸

City of Hope Comprehensive Cancer Center ( Site 5002), Duarte, California, United States

🇺🇸

Cedars-Sinai Medical Center ( Site 5045), Los Angeles, California, United States

and more 54 locations

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

First Posted Date
2021-07-09
Last Posted Date
2024-06-21
Lead Sponsor
Yale University
Target Recruit Count
56
Registration Number
NCT04955743
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

First Posted Date
2021-07-02
Last Posted Date
2024-12-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
862
Registration Number
NCT04949256
Locations
🇨🇷

PROCLINICAL Pharma ( Site 0904), San José, San Jose, Costa Rica

🇨🇳

Shanxi Provincial Cancer Hospital ( Site 8019), Taiyuan, Shanxi, China

🇨🇳

West China Hospital of Sichuan University ( Site 8048), Chengdu, Sichuan, China

and more 192 locations

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

First Posted Date
2021-06-24
Last Posted Date
2024-12-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
110
Registration Number
NCT04938817
Locations
🇺🇸

Banner MD Anderson Cancer Center ( Site 0152), Gilbert, Arizona, United States

🇺🇸

Northside Hospital-Northside Hospital Oncology Network ( Site 0156), Atlanta, Georgia, United States

🇺🇸

Parkview Research Center at Parkview Regional Medical Center ( Site 0180), Fort Wayne, Indiana, United States

and more 44 locations

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

First Posted Date
2021-06-11
Last Posted Date
2024-11-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT04924101
Locations
🇺🇸

UPMC Hillman Cancer Center ( Site 0127), Pittsburgh, Pennsylvania, United States

🇺🇸

MFSMC-HJWCI-Oncology Research ( Site 0128), Baltimore, Maryland, United States

🇺🇸

Cleveland Clinic-Taussig Cancer Center ( Site 0116), Cleveland, Ohio, United States

and more 46 locations

Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

First Posted Date
2021-06-03
Last Posted Date
2023-02-06
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
50
Registration Number
NCT04911959
Locations
🇨🇳

Weilin Wang, Hangzhou, None Selected, China

🇨🇳

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy